Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
06 November 2012Website:
http://www.canfite.comNext earnings report:
09 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:24:28 GMTDividend
Analysts recommendations
Institutional Ownership
CANF Latest News
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating.
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that its VP of Business Development, Dr. Sari Fishman, will hold 23 partnering meetings with Biotech & Pharma companies, who showed interest in partnering with Can-Fite. The meetings will take place during the Bio International Convention 2024 in.
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcinoma.
What type of business is Can-Fite BioPharma?
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
What sector is Can-Fite BioPharma in?
Can-Fite BioPharma is in the Healthcare sector
What industry is Can-Fite BioPharma in?
Can-Fite BioPharma is in the Biotechnology industry
What country is Can-Fite BioPharma from?
Can-Fite BioPharma is headquartered in Israel
When did Can-Fite BioPharma go public?
Can-Fite BioPharma initial public offering (IPO) was on 06 November 2012
What is Can-Fite BioPharma website?
https://www.canfite.com
Is Can-Fite BioPharma in the S&P 500?
No, Can-Fite BioPharma is not included in the S&P 500 index
Is Can-Fite BioPharma in the NASDAQ 100?
No, Can-Fite BioPharma is not included in the NASDAQ 100 index
Is Can-Fite BioPharma in the Dow Jones?
No, Can-Fite BioPharma is not included in the Dow Jones index
When does Can-Fite BioPharma report earnings?
The next expected earnings date for Can-Fite BioPharma is 09 July 2024